Dyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low – Should You Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) reached a new 52-week low during trading on Wednesday . The company traded as low as $10.88 and last traded at $10.91, with a volume of 377079 shares. The stock had previously closed at $11.40.

Wall Street Analyst Weigh In

DYN has been the subject of several research reports. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th. JPMorgan Chase & Co. decreased their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Stock Performance

The firm’s fifty day simple moving average is $13.33 and its 200 day simple moving average is $23.66. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -3.22 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. Analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Activity

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 6,237 shares of company stock worth $77,760. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC grew its position in Dyne Therapeutics by 47.3% in the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after purchasing an additional 2,189,339 shares during the period. Jefferies Financial Group Inc. purchased a new stake in Dyne Therapeutics in the 4th quarter valued at $42,408,000. Norges Bank purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $22,384,000. Finally, Point72 Asset Management L.P. lifted its position in shares of Dyne Therapeutics by 802.3% during the 4th quarter. Point72 Asset Management L.P. now owns 924,681 shares of the company’s stock worth $21,785,000 after buying an additional 822,201 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.